Group 1 - The "Annual Outstanding Healthcare Enterprises" award recognizes companies in the Chinese healthcare industry that excel in innovation, technological leadership, market influence, social value, and sustainable development [4] - The award winners include Alibaba Health (00241.HK), Anxuyuan, Baize Medical (02609.HK), Gushengtang (02273.HK), Haijia Medical (06078.HK), Jinhua Medical Group (01110.HK), Kangchen Pharmaceutical (01681.HK), Ping An Good Doctor (01833.HK), Weitai Medical-B (02235.HK), and Xinwei Medical-B (06609.HK) [1] - The selection process involved quantitative data analysis and an expert review panel to determine the final results [4] Group 2 - The "Jin Ge Award" aims to create a reference for the investment community by highlighting the most valuable listed companies and unicorns in China [4] - The evaluation covers all listed companies and unicorns on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [4]

Group 1 - The core viewpoint of the article highlights the recent trading activity of southbound funds in Baize Medical (02609.HK), indicating a net increase of 55.98 thousand shares on December 17, while also noting a cumulative net reduction of 74.4 thousand shares over the last five trading days and 198.78 thousand shares over the last twenty trading days [1] - As of now, southbound funds hold 61.51 million shares of Baize Medical, which represents 4.65% of the company's total issued ordinary shares [1] - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology medical services throughout the entire cycle, including screening, diagnosis, treatment, and rehabilitation [1] Group 2 - The company's operations encompass hospital business, hospital management services, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - Services provided by the company include cancer diagnosis, treatment, rehabilitation, end-of-life care, early cancer screening, cancer vaccination, and health management services for potential healthy populations [1] - The company primarily conducts its business in the Chinese market [1]

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (HKD) closed at 4302.26 points, up 1.09% with a trading volume of 10.694 billion HKD and a turnover rate of 1.0% [1] - Among the constituent stocks, 39 stocks rose, with Baize Medical leading with a 5.14% increase, while 16 stocks fell, with Furuide leading the decline at 3.23% [1] Fund Flow Analysis - The total net inflow of main funds into the Shenzhen-Hong Kong Stock Connect Medical Index constituents was 80.9503 million HKD, while speculative funds saw a net outflow of 283 million HKD, and retail investors had a net inflow of 202 million HKD [2]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4383.23 points, up 0.98% with a trading volume of 9.693 billion yuan and a turnover rate of 1.0% [1] - Among the constituent stocks, 39 stocks rose, with Baize Medical leading with a 5.14% increase, while 16 stocks fell, with Furuide leading the decline at 3.23% [1] - The net inflow of main funds into the Shenzhen-Hong Kong Medical Index constituents totaled 80.9503 million yuan, while speculative funds saw a net outflow of 283 million yuan, and retail investors had a net inflow of 202 million yuan [2] Group 1 - The Shenzhen-Hong Kong Medical Index reported a positive performance with a 0.98% increase [1] - Baize Medical showed the highest gain among constituents with a 5.14% rise [1] - Furuide experienced the largest decline with a 3.23% drop [1] Group 2 - The total net inflow of main funds was 80.9503 million yuan [2] - Speculative funds experienced a significant net outflow of 283 million yuan [2] - Retail investors contributed to a net inflow of 202 million yuan [2]

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 142.44 million shares on December 11, 2025, marking a total net reduction of 204.06 million shares over the last five trading days [1][2] - Over the past 20 trading days, southbound funds have reduced their holdings in Baize Medical on 10 occasions, resulting in a cumulative net reduction of 271.32 million shares [1][2] - As of now, southbound funds hold 60.83 million shares of Baize Medical, which accounts for 4.6% of the company's total issued ordinary shares [1][2] Group 2 - Baize Medical Group is primarily engaged in investment and provision of medical-related services, focusing on oncology medical services [2] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation, and operates mainly in the Chinese market [2]

Core Insights - The latest ESG rating results published by Huazheng Index show that Baize Medical (02609.HK) received a CCC rating, ranking 15th out of 16 healthcare providers listed on the Hong Kong stock exchange [1] ESG Rating Summary - Environmental Score: Baize Medical scored 54.89 with a rating of C, ranking 15th in the industry. The evaluation criteria include climate change, resource utilization, environmental pollution, and environmental management [1] - Social Score: The company achieved a score of 70.42 with a rating of B, also ranking 15th. This score is based on factors such as human capital, suppliers, social contribution, and data security and privacy [1] - Governance Score: Baize Medical received a score of 80.2 with a rating of BBB, ranking 7th in the industry. Governance factors assessed include shareholder rights, governance structure, disclosure quality, governance risks, external sanctions, and business ethics [1]

Core Insights - As of December 10, 30 stocks reached their 52-week highs, with Design Metropolis (01545), Platinum Holdings (00459), and China Boton (03318) leading the increase rates at 40.82%, 35.48%, and 30.23% respectively [1][2] 52-Week Highs - Design Metropolis (01545) closed at 0.124, with a peak of 0.138, achieving a high rate of 40.82% [1] - Platinum Holdings (00459) closed at 0.121, with a peak of 0.126, achieving a high rate of 35.48% [1] - China Boton (03318) closed at 2.090, with a peak of 2.800, achieving a high rate of 30.23% [1] - Other notable stocks include: - China New Holdings (08125) at 25.00% [1] - Qiaoyang International Holdings (08070) at 14.46% [1] 52-Week Lows - The stock with the largest decline was Jingye Mingbang Group (02231), which fell to 0.099, a decrease of 26.40% [2] - Other significant declines included: - Zhonggang Petroleum (00632) at -16.40% [2] - Guofu Hydrogen Energy (02582) at -13.31% [2] - Additional stocks with notable declines: - Haotian International Construction Investment (01341) at -11.11% [2] - Jiaming Group Holdings (01271) at -10.00% [2]

Core Viewpoint - Southbound funds increased their holdings in Baize Medical (02609.HK) by 10,200 shares on December 9, indicating a potential positive sentiment towards the company [1] Group 1: Southbound Fund Activity - Over the past 5 trading days, there was a net reduction of 382,800 shares, with southbound funds reducing their holdings on one day [1] - In the last 20 trading days, there were 10 days of net reductions totaling 2,009,400 shares [1] - Currently, southbound funds hold 62,471,400 shares of Baize Medical, representing 4.73% of the company's total issued ordinary shares [1] Group 2: Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - The company also conducts early cancer screening, tumor vaccination, and health management services for potential healthy populations, primarily in the Chinese market [1]

Core Insights - The forum "Integration and Precision Rehabilitation - 2025 Cancer Rehabilitation Forum" held in Tianjin aims to enhance the quality of life for cancer patients through innovative rehabilitation practices and multidisciplinary collaboration [1][4][5]. Group 1: Event Overview - The forum was organized by the Tianjin Anti-Cancer Association and Baize Medical Group, gathering experts from various fields including oncology, rehabilitation, psychology, and traditional Chinese medicine [1][2]. - The event focused on the integration of cancer rehabilitation within the full-cycle management model, emphasizing the importance of improving patient quality of life alongside survival rates [1][4]. Group 2: Industry Context - The "Healthy China Action (2019-2030)" highlights the significant impact of cancer on public health and stresses the need for rehabilitation treatment [1]. - The "Healthy China Action - Cancer Prevention and Control Implementation Plan (2023-2030)" calls for standardized management of diagnosis and treatment, including rehabilitation guidance and psychological support [1]. Group 3: Company Initiatives - Baize Medical Group aims to establish itself as a leading cancer full-cycle medical group in China, operating six for-profit hospitals and managing two non-profit hospitals [2]. - The group has proposed a comprehensive approach to cancer management, focusing on prevention, screening, diagnosis, treatment, and rehabilitation [5][12]. Group 4: Expert Contributions - Experts at the forum discussed various aspects of cancer rehabilitation, including the role of traditional Chinese medicine and the need for multidisciplinary approaches to address challenges faced by young breast cancer patients [8][9]. - The forum also featured discussions on symptom management and the importance of personalized rehabilitation plans to enhance patient quality of life [9][10]. Group 5: Future Directions - The forum resulted in the formation of the "Cancer Rehabilitation Expert Consensus (2025)," which aims to standardize clinical practices in cancer rehabilitation [12]. - The event served as a platform for collaboration among leading medical institutions, fostering innovation in cancer rehabilitation practices [12][14].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02609 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,318,466,823 | | | | 1,318,466,823 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,318,466,823 | | 0 | | 1,318,466,823 | 第 2 頁 共 10 ...